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journal homepage: http: / /www.kjms-onl ine.comLETTER TO THE EDITORPyoderma gangrenosum: Intractable leg ulcers
in Sjogren’s syndromeTo the Editor,
I am writing with regard to a patient with pyoderma
gangrenosum; a rare skin disease. This 52-year-old woman
had multiple wounds with poor healing over her right
lower leg and ankle for 3 years after a traffic accident.
The wounds were initially small, abrasive, and shallow,
and subsequently progressed to become a deep ulcer with
some necrotic tissue (Fig. 1A and B). She did not have
diabetes, hypertension, or hyperlipidemia. A blood test
revealed a platelet count of 40,000/mL, white blood cell
count of 4300/mL, hemoglobin level of 10.5 g/dL, and C-
reactive protein level of 1.06 mg/L. A bone marrow study
showed reactive marrow to peripheral destruction, and an
immunological study revealed that she was negative for
rheumatoid factor, positive for Ro, La, and double-
stranded DNA antibodies, and had an antinuclear anti-
body ratio of 1:1280. The levels of C3 and C4 were
modestly lower at 70 mg/dL and 14 mg/dL, respectively.
She also complained of dry eyes and mouth. A subsequent
Schirmer’s test was positive, and salivary scintigraphy
showed delayed uptake, suggesting moderate sialoadeni-
tis over both parotid glands and the right submandibular
gland. Based on the above findings, Sjogren’s syndrome
was diagnosed.
A skin biopsy revealed inflammatory cells with neutro-
philic and lymphoplasmacytic infiltration, however, there
was no evidence of thrombosis or vasculitis (Fig. 1C and D).
These features were compatible with pyoderma
gangrenosum.
Pyoderma gangrenosum is often associated with under-
lying diseases and is a rare ulcerative skin disease [1e3]. It
is defined as an inflammatory, reactive, noninfective, non-
neoplastic skin disease, and is associated with anti-
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However, Sjogren’s syndrome as the underlying morbidity
has rarely been reported in the literature [4].
There are several variants of pyoderma gangrenosum
including ulcerative, pustular, bullous, and vegetative
types, of which the ulcerative type is the most common [1].
The skin biopsy of this patient demonstrated neutrophil and
lymphoplasma cell infiltration with necrotic surroundings,
compatible with pyoderma gangrenosum.
The blood, immunological, and imaging studies showed
that the patient had primary Sjogren’s syndrome. Systemic
lupus erythematous and Sjogren’s syndrome have several
overlapping features in the early stage of the disease
course. However, our patient only had three features of
lupus, namely antinuclear antibody, double-stranded DNA
antibody, and thrombocytopenia, which did not fulfill the
criteria for systemic lupus erythematous.
The cause of the intractable leg wounds was important
in our patient. According to her C-reactive protein level,
white cell count, and clinical course, an infection was
less likely. In addition, the disease course, clinical data,
and pathological report impressed an inflammatory
autoimmune disease, which met the diagnosis of Sjog-
ren’s syndrome. Therefore, mini-pulse therapy with
120 mg/day methylprednisolone was given for 3 consec-
utive days. The prednisolone dose was then maintained
at 15 mg twice daily, and 200 mg/day hydroxy-
chloroquine, 50 mg/day azathioprine, and 200 mg/day
dapsone were added [3,5]. Her wounds healed progres-
sively (Fig. 1E and F), and the platelet count improved to
140,000/mL.
In summary, this case highlights the successful treat-
ment of a patient with pyoderma gangrenosum with Sjog-
ren’s syndrome. We used mini-pulse steroids as the
induction therapy, and then maintained this with a com-
bination of dapsone [5] and azathioprine with tapering of
prednisolone to a lower dose [3].ed by Elsevier Taiwan LLC. All rights reserved.
Figure 1. (A) Initial picture, wound with deep ulcer and some necrotic tissue. (B) Initial picture lateral view, wound with deep
ulcer and some necrotic tissue. (C,D) Pathology, inflammation with neutrophilic and lymphoplasmacytic infiltration. (E) Post-
treatment. (F) Post-treatment, lateral view.
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